What type of study is this?

This is a In Vitro Study study.

What question did this study set out to answer?

This research aims to evaluate GB3226's effectiveness as a dual inhibitor against ENL-YEATS and FLT3 in acute myeloid leukemia (AML).

December 8, 2025Blood

GB3226, a novel, orally active, first-in-class small molecule inhibitor of ENL-yeats and FLT3 kinase for the treatment of Relapsed/Refractory Acute Myeloid Leukemia

View Full Paper

Ask AI

Bookmark

This research aims to evaluate GB3226's effectiveness as a dual inhibitor against ENL-YEATS and FLT3 in acute myeloid leukemia (AML).
Conducted ligand binding assays to determine GB3226's IC50 values against ENL-YEATS and FLT3.
Examined the anti-leukemic effects of GB3226 in MV4;11 and MOLM13 cell lines and patient samples.
Investigation of pharmacokinetics, safety, and tolerability in preclinical models including toxicology studies.
GB3226 showed potent inhibitory effects on ENL-YEATS and FLT3 with IC50 values of 185 nM and 7 nM respectively.
Demonstrated significant tumor regression in MV4;11 xenograft models, with prolonged survival observed.
Well tolerated in pilot toxicology studies with no severe adverse effects.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Preclinical findings demonstrate that GB3226 effectively reduces leukemia burden in patient samples, suggesting it may enhance therapy when combined with venetoclax.

Cite This Study

Stacia Kargman (2025) studied this question.

synapsesocial.com/papers/69362f6c4fa91c937236dfa7 https://doi.org/10.1182/blood-2025-6106

View Full Paper

Ask AI

Bookmark

Implication

Preclinical findings demonstrate that GB3226 effectively reduces leukemia burden in patient samples, suggesting it may enhance therapy when combined with venetoclax.

GB3226, a novel, orally active, first-in-class small molecule inhibitor of ENL-yeats and FLT3 kinase for the treatment of Relapsed/Refractory Acute Myeloid Leukemia

Key Points

Discussion

Implication

Cite This Study

GB3226, a novel, orally active, first-in-class small molecule inhibitor of ENL-yeats and FLT3 kinase for the treatment of Relapsed/Refractory Acute Myeloid Leukemia

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider